Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Spring LM, Wander SA, Andre F, Moy B, et al. Lancet 2020;395:817-827.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Spring LM, Wander SA, Andre F, Moy B, et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 2020;395:817-827.
PMID: 32145796